Mesoblast (ASX:MSB) expanded its coverage for Ryoncil to 104 million US government- and private-insured lives, according to a Thursday filing with the Australian bourse.

Ryoncil is approved by the US Food and Drug Administration for mesenchymal stromal cell therapy.

It is the only approved therapy for steroid-refractory acute graft versus host disease (SR-aGvHD) in children aged two months and older, a separate filing showed.

Mesoblast's shares were up nearly 2% in recent trade.